silen-c3 trial
DESCRIPTION
Treatment for 12 or 24 weeks with BI201335 combined with peg-interferon alfa-2a and ribavirin (PR) in treatment-naïve patients with chronic genotype-1 HCV infection: Results of the SILEN-C3 trial. SILEN-C3 trial . Main inclusion criteria. Baseline characteristics. Virologic response. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/1.jpg)
Treatment for 12 or 24 weeks with BI201335 combined with peg-interferon alfa-2a and ribavirin (PR) in
treatment-naïve patients with chronic genotype-1 HCV infection:
Results of the SILEN-C3 trial
![Page 2: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/2.jpg)
![Page 3: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/3.jpg)
SILEN-C3 trial
![Page 4: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/4.jpg)
Main inclusion criteria
![Page 5: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/5.jpg)
Baseline characteristics
![Page 6: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/6.jpg)
Virologic response
![Page 7: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/7.jpg)
Treatment outcome
![Page 8: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/8.jpg)
Time to undetectable HCV RNAcorrelated with SVR
![Page 9: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/9.jpg)
Adverse events: overall summary
![Page 10: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/10.jpg)
Most common adverse events (>15% in any group)
![Page 11: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/11.jpg)
Summary
![Page 12: SILEN-C3 trial](https://reader036.vdocuments.mx/reader036/viewer/2022062410/56816315550346895dd38e00/html5/thumbnails/12.jpg)
Acknowledgements